• Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
    • Staniszewska M, Iking J, Lückerath K, Hadaschik B, Herrmann K, Ferdinandus J, Fendler WP.
    • Nucl Med Biol. 2021 Apr 9;96-97:101-111. doi: 10.1016/j.nucmedbio.2021.03.009. Epub ahead of print.
    • Review
    • Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States.
    • Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R.
    • Transl Androl Urol. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439.
    • Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    • Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.
    • Eur J Cancer. 2021 Feb 22;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub ahead of print.
    • Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
    • Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC.
    • Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005801. doi: 10.1101/mcs.a005801.
    • Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    • Leon P, Cancel-Tassin G, Bourdon V, Buecher B, Oudard S, Brureau L, Jouffe L, Blanchet P, Stoppa-Lyonnet D, Coulet F, Sobol H, Cussenot O.
    • Prostate. 2021 Feb 18. doi: 10.1002/pros.24109. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Identification of Germline Genetic Variants That Increase Prostate Cancer Risk and Influence Development of Aggressive Disease.
    • Saunders EJ, Kote-Jarai Z, Eeles RA.
    • Cancers (Basel). 2021 Feb 12;13(4):E760. doi: 10.3390/cancers13040760.
    • Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    • Su D, Wu B, Shi L.
    • Front Pharmacol. 2021 Jan 26;11:610601. doi: 10.3389/fphar.2020.610601.
  • LitAlert ~~ GeneLit.com

    • Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms.
    • Tukachinsky H, Madison RW, Chung JH, Gjoerup O, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons AD, Loehr A, Venstrom JM, Oxnard GR.
    • Clin Cancer Res. 2021 Feb 9. doi: 10.1158/1078-0432.CCR-20-4805. Epub ahead of print.
    • Management of a Prostate Cancer Patient with inherited germline BRCA1 and BRCA2 mutations, a Case Report.
    • Hemal S, DeWitt-Foy M, Klein EA.
    • Urology. 2021 Feb 5:S0090-4295(21)00120-5. doi: 10.1016/j.urology.2020.11.076. Epub ahead of print.
    • Case report